NCM · Biotechnology

Filana Therapeutics, Inc. (FLNA) Stock

$0.82 +0.39% NCM: FLNA Healthcare

Valuation

MetricValue
Price$0.82
Market Cap$39.46M
P/E Ratio-1.07
P/B Ratio0.71
P/S Ratio0.00
EPS (TTM)$-1.88
52-Week High$4.98
52-Week Low$0.67
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-58.78%
ROA-40.69%
ROCE-72.12%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio2.23

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-33.0M$-80.0M$-106.0M$-141.0M$-95.0M
Net Profit$-32.0M$-76.0M$-97.0M$-24.0M$-91.0M
EPS$-0.82$-1.90$-2.32$-1.46$-1.88
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets————$118.0M
Total Liabilities————$44.0M
Cash————$96.0M
Borrowings$0$0$0$0$0

Latest News

Data I/O And 2 Other Promising Penny Stocks To Watch Simply Wall St. · May 29, 2026 Filana Therapeutics Reports Q1 2026 Financial Results and Business Update GlobeNewswire · May 7, 2026 Filana Therapeutics Presents TSC-Related Epilepsy Program at Eilat XVIII GlobeNewswire · May 5, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow————$-32.0M
Investing Cash Flow————$-1.0M
Financing Cash Flow————$0
Net Cash Flow————$-33.0M
Free Cash Flow$0$0$0$0$-33.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.01
EV / EBITDA0.90
FCF Yield-45.42%
Quick Ratio2.08
Interest Coverage0.00
Return 1Y-48.31%
Return 3Y-95.12%
Return 5Y-98.66%

Ownership

Insiders Held2.05%
Institutions Held28.59%
Institutions Float Held29.19%
Institutional HolderSharesReport Date
Marshall Wace LLP2,012,5432026-03-31
Two Sigma Investments, LP1,988,8142026-03-31
Vanguard Capital Management LLC1,930,9432026-03-31
Blackrock Inc.1,414,5142026-03-31
Geode Capital Management, LLC596,2422026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $336.64 -1.11% 38.93 $4.94T 0.32%
MSFTMicrosoft Corporation $535.07 +2.38% 28.68 $3.97T 0.76%
GOOGLAlphabet Inc. $351.66 +0.97% 16.94 $4.26T 0.26%
AMZNAmazon.com, Inc. $262.43 +3.29% 19.82 $2.82T 0.00%
METAMeta Platforms, Inc. $718.67 -0.31% 27.93 $1.83T 0.28%

About Filana Therapeutics, Inc.

Filana Therapeutics, Inc. is led by CEO Richard Jon Barry, employs 20 people, headquartered in US, publicly traded since 2000.

Filana Therapeutics, Inc. (FLNA) stock trades at $0.82 with a market capitalization of $39.46M. The stock is valued at a price-to-earnings (P/E) ratio of -1.07, price-to-book of 0.71, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.67 and $4.98, and currently trades 83.5% below its 52-week high.

On profitability, Filana Therapeutics, Inc. generates a return on equity (ROE) of -58.78%, return on capital employed of -72.12%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides